×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
EVOK – evoke pharma, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
EVOK
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/30
02:34 am
evok
Evoke Pharma, Inc. (NASDAQ: EVOK) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
Evoke Pharma, Inc. (NASDAQ: EVOK) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
12/22
02:07 am
evok
Evoke Pharma, Inc. (NASDAQ: EVOK) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Medium
Report
Evoke Pharma, Inc. (NASDAQ: EVOK) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
12/19
08:44 am
evok
Evoke Pharma Highlights GIMOTI as a Leading Solution for Gastroparesis Treatment as Domperidone Supply Ends [Yahoo! Finance]
High
Report
Evoke Pharma Highlights GIMOTI as a Leading Solution for Gastroparesis Treatment as Domperidone Supply Ends [Yahoo! Finance]
12/19
08:30 am
evok
Evoke Pharma Highlights GIMOTI as a Leading Solution for Gastroparesis Treatment as Domperidone Supply Ends
High
Report
Evoke Pharma Highlights GIMOTI as a Leading Solution for Gastroparesis Treatment as Domperidone Supply Ends
12/14
02:01 am
evok
Evoke Pharma, Inc. (NASDAQ: EVOK) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
Evoke Pharma, Inc. (NASDAQ: EVOK) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
12/6
02:18 am
evok
Evoke Pharma, Inc. (NASDAQ: EVOK) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
Evoke Pharma, Inc. (NASDAQ: EVOK) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
12/3
08:44 am
evok
Evoke Pharma Receives Notices of Allowance for Two Additional US Patent Applications Protecting GIMOTI® [Yahoo! Finance]
Medium
Report
Evoke Pharma Receives Notices of Allowance for Two Additional US Patent Applications Protecting GIMOTI® [Yahoo! Finance]
12/3
08:30 am
evok
Evoke Pharma Receives Notices of Allowance for Two Additional US Patent Applications Protecting GIMOTI®
Medium
Report
Evoke Pharma Receives Notices of Allowance for Two Additional US Patent Applications Protecting GIMOTI®
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/15
04:31 pm
evok
Form 3 Evoke Pharma Inc For: Nov 06 Filed by: Harkey Wilmot B.
Medium
Report
Form 3 Evoke Pharma Inc For: Nov 06 Filed by: Harkey Wilmot B.
11/14
01:09 pm
evok
Form SC 13G/A Evoke Pharma Inc Filed by: LYTTON LAURENCE W
Low
Report
Form SC 13G/A Evoke Pharma Inc Filed by: LYTTON LAURENCE W
11/14
09:20 am
evok
Form SC 13G/A Evoke Pharma Inc Filed by: Altium Capital Management LP
Medium
Report
Form SC 13G/A Evoke Pharma Inc Filed by: Altium Capital Management LP
11/7
04:16 pm
evok
Form 10-Q Evoke Pharma Inc For: Sep 30
Low
Report
Form 10-Q Evoke Pharma Inc For: Sep 30
11/7
04:15 pm
evok
Form 8-K Evoke Pharma Inc For: Nov 07
Low
Report
Form 8-K Evoke Pharma Inc For: Nov 07
11/6
04:32 pm
evok
Form SC 13D/A Evoke Pharma Inc Filed by: Nantahala Capital Management, LLC
Medium
Report
Form SC 13D/A Evoke Pharma Inc Filed by: Nantahala Capital Management, LLC
10/29
07:47 pm
evok
Form SC 13G/A Evoke Pharma Inc Filed by: HIRSCHMAN ORIN
Low
Report
Form SC 13G/A Evoke Pharma Inc Filed by: HIRSCHMAN ORIN
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/14
Form DEF 14A Evoke Pharma Inc For: May 27
11.6%
6/27 Evoke Pharma Requests Type A FDA Meeting to Plan for Resubmission of Gimoti™ NDA 6.0%
10/16 Evoke Pharma Inc (NASDAQ: EVOK) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $1.00 price target on the stock. 5.8%
12/4 Evoke Pharma Inc (NASDAQ: EVOK) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $1.75 price target on the stock. 3.9%
5/28 Evoke Pharma Inc (NASDAQ: EVOK) had its "hold" rating re-affirmed by analysts at HC Wainwright. 3.6%
3/3 Form 4 Evoke Pharma Inc For: Feb 28 Filed by: Gonyer David A 2.9%
5/7 Evoke Pharma Inc (NASDAQ: EVOK) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 2.9%
9/17 Evoke Pharma Completes Manufacturing of Commercial Scale Registration Batches of Gimoti™ 2.1%
6/19 Form 4 Evoke Pharma Inc For: Jun 17 Filed by: Gonyer David A 2.0%
11/13 Evoke Pharma Granted 180-Day Extension by Nasdaq Regarding Minimum Bid Price 1.1%
6/27 Evoke Pharma Requests Type A FDA Meeting to Plan for Resubmission of Gimoti™ NDA 6.0%
10/16 Evoke Pharma Inc (NASDAQ: EVOK) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $1.00 price target on the stock. 5.8%
12/4 Evoke Pharma Inc (NASDAQ: EVOK) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $1.75 price target on the stock. 3.9%
5/28 Evoke Pharma Inc (NASDAQ: EVOK) had its "hold" rating re-affirmed by analysts at HC Wainwright. 3.6%
3/3 Form 4 Evoke Pharma Inc For: Feb 28 Filed by: Gonyer David A 2.9%
5/7 Evoke Pharma Inc (NASDAQ: EVOK) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 2.9%
9/17 Evoke Pharma Completes Manufacturing of Commercial Scale Registration Batches of Gimoti™ 2.1%
6/19 Form 4 Evoke Pharma Inc For: Jun 17 Filed by: Gonyer David A 2.0%
11/13 Evoke Pharma Granted 180-Day Extension by Nasdaq Regarding Minimum Bid Price 1.1%
TOP News Decliners
1/21
Form 8-K Evoke Pharma Inc For: Jan 21
-30.0%
8/8 Form 8-K Evoke Pharma Inc For: Aug 08 -15.6%
11/18 Evoke Pharma up 32% [Seeking Alpha] -11.3%
12/20 Form 8-K Evoke Pharma Inc For: Dec 20 -10.7%
3/12 Evoke Pharma Reports Fourth Quarter and Full Year 2019 Financial Results -9.9%
5/8 Form 10-Q Evoke Pharma Inc For: Mar 31 -9.4%
3/26 Evoke Pharma Inc (NASDAQ: EVOK) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -7.5%
7/10 Evoke Pharma Inc (NASDAQ: EVOK) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -6.0%
1/23 Evoke Pharma Enters Commercialization Agreement with EVERSANA Life Sciences for Gimoti™ -4.3%
12/2 Evoke Pharma Regains Compliance with Nasdaq Minimum Bid Requirement -4.2%
8/8 Form 8-K Evoke Pharma Inc For: Aug 08 -15.6%
11/18 Evoke Pharma up 32% [Seeking Alpha] -11.3%
12/20 Form 8-K Evoke Pharma Inc For: Dec 20 -10.7%
3/12 Evoke Pharma Reports Fourth Quarter and Full Year 2019 Financial Results -9.9%
5/8 Form 10-Q Evoke Pharma Inc For: Mar 31 -9.4%
3/26 Evoke Pharma Inc (NASDAQ: EVOK) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -7.5%
7/10 Evoke Pharma Inc (NASDAQ: EVOK) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -6.0%
1/23 Evoke Pharma Enters Commercialization Agreement with EVERSANA Life Sciences for Gimoti™ -4.3%
12/2 Evoke Pharma Regains Compliance with Nasdaq Minimum Bid Requirement -4.2%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: